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ABSTRACT
Troyer syndrome is a hereditary spastic paraplegia characterized by lower limb
spasticity, weakness, mild mental retardation and shortness of stature. Troyer syndrome
is caused by a frameshift mutation in the SPG20 gene, which encodes the protein spartin.
This mutation leads to complete loss of spartin’s expression. Spartin protein contains two
major conserved domains: an N-terminal microtubule interacting and trafficking (MIT)
domain and a C-terminal plant-related senescence domain. The plant-related senescence
domain of spartin protein is highly conserved and is present in over 150 proteins
expressed in different species. The function of this domain in spartin and other proteins
is completely unknown.
In the present study, we have found that the plant-related senescence domain of
spartin binds at least 11 phospholipids. The Arabidopsis thaliana early-responsive to
dehydration 7 (ERD7) protein also contains a senescence domain, and our findings show
that it binds a similar array of phospholipids as the plant-related senescence domain
present in spartin. Furthermore, mutation of evolutionarily-conserved positively-charged
amino acids in the senescence domain of spartin resulted in no binding to phospholipids.
These data indicate that spartin associates with negatively-charged phospholipids via its
plant-related senescence domain.
Phospholipids are an important component of intracellular membranes and play a
role in many cellular processes, including signal transduction, membrane trafficking, and
x

cellular division. Defects in cell division have been shown in neurological disorders that
involve mental retardation. Knock-down of spartin results in impaired cell division, with
many cells arrested in cytokinesis. The phospholipid phosphatidylinositol 3-phosphate
(PI3P) is present at midbodies during cytokinesis, where it recruits proteins required for
abscission. Our findings demonstrated that spartin colocalizes with PI3P at midbodies.
We also showed that knock-down of spartin results in a decreased number of cells with
PI3P at midbodies compared to control cells. These results suggest that spartin transports
PI3P to midbodies.
There are several known lipid transfer proteins that shuttle phospholipids between
organellar membranes to maintain the correct composition of lipids at each membrane.
Defects in lipid transfer proteins have been shown to play a role in neurological
dysfunctions. Our data suggest that spartin functions as a novel lipid transfer protein that
shuttles negatively-charged phospholipids between intracellular membranes via its plantrelated senescence domain.
The pathophysiology of Troyer syndrome may be due in part to defective
maintenance and transport of phospholipids between membranes of different intracellular
organelles.

xi

CHAPTER 1
INTRODUCTION

Troyer Syndrome and Spartin Protein
The hereditary spastic paraplegias (HSPs) are a group of neurological disorders
that affect about 3-10 people per 100,000 globally (McMonagle et al., 2002; Salinas et
al., 2008). Thus far, 48 genetic loci have been identified, and about 20 genes have been
reported to play a role in HSP development (Dion et al., 2009; Durr, 2008). The major
HSP symptoms are progressive lower limb spasticity and weakness (Cross and
McKusick, 1967), which are caused by degeneration of the axons of the upper motor
neurons of the corticospinal tract (Salinas et al., 2008; Soderblom and Blackstone, 2006).
When additional symptoms (such as mild mental retardation and short stature) are
involved, the disorders are classified as “complicated,” rather than “pure” (Cross and
McKusick, 1967; Harding, 1983).
One of these disorders, Troyer syndrome, is an autosomal recessive form that
presents in early childhood (Cross and McKusick, 1967; Milewska et al., 2009). Troyer
syndrome is caused by a frameshift mutation in the SPG20 gene, encoding the protein
spartin (spastic paraplegia autosomal recessive Troyer syndrome) (Patel et al., 2002).
This mutation introduces a premature stop codon leading to a complete loss of

1

2

spartin’s expression in fibroblasts and lymphoblasts derived from Troyer syndrome
patients (Bakowska et al., 2008).
Spartin is a 666 amino acid protein with two main conserved domains: an Nterminal microtubule interacting and trafficking (MIT) domain and C-terminal plantrelated senescence domain (Ciccarelli et al., 2003). The MIT domain is known to
interact with proteins of the endosomal sorting complex required for transport (ESCRT),
which are important in multivesicular body formation, membrane abscission during
cytokinesis, and virus budding (Hurley, 2008; McDonald and Martin-Serrano, 2009).
The function of the plant-related senescence domain is currently unknown.
Lack of spartin expression is known to cause the symptoms of Troyer Syndrome,
but the specific role of spartin in disease has yet to be determined. Spartin localizes
mainly to the cytoplasm, but it also associates with many organelles, including the
plasma membrane, mitochondria, trans-Golgi network, midbodies and lipid droplets
(Bakowska et al., 2005; Bakowska et al., 2007; Eastman et al., 2009; Hooper et al., 2010;
Lu et al., 2006; Robay et al., 2006). The wide variety of organelles with which spartin
has been shown to interact has led to questions about how spartin could have discreet
functions at so many intracellular sites (Milewska et al., 2009). Thus far, spartin has
been shown to play a role in epidermal growth factor receptor internalization (Bakowska
et al., 2007), mitochondrial function (Joshi and Bakowska, 2011), and lipid droplet
turnover (Eastman et al., 2009; Hooper et al., 2010).

Plant-Related Senescence Domain
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The plant-related senescence domain found in spartin is highly conserved and is
present in over 150 proteins expressed in widely diverse species ranging from vertebrates
to insects to plants, such as Homo sapiens, Drosophila mojavensis and Arabidopsis
thaliana (Fig. 1) (Ciccarelli et al., 2003; Gibbs et al., 1997; Panavas et al., 1999). This
domain was named because it is found in proteins whose expression is up-regulated
during situations of dehydration and senescence in plants (Panavas et al., 1999). The
presence of this domain in many proteins in a variety of species suggests that it has an
important and conserved role in cells. It is astonishing that the function of such a
conserved domain is currently unknown. Our recent studies show that the plant-related
senescence domain of spartin binds to cardiolipin (a major, negatively-charged
phospholipid of the inner mitochondrial membrane), and this interaction is important in
mitochondrial function (Joshi and Bakowska, 2011). This finding led us to investigate
whether spartin also binds to other negatively-charged phospholipids. Spartin interacts
with multivesicular bodies (MVBs) through the resident MVB protein increased sodium
tolerance 1 (Ist1) (Renvoise et al., 2010), and evidence suggests that spartin interacts with
lipid droplets and possibly endosomes via lipid droplet tail-interacting protein of 47 kD
(TIP47) (Eastman et al., 2009). Because spartin has no transmembrane domain, it is
reasonable to suggest that spartin’s associations with resident membrane phospholipids
and proteins may play a role in its interactions with intracellular organelles (Ciccarelli et
al., 2003).

Phospholipids
3

4

Plants

Fungi

Animals

Figure 1. Phylogenetic relationships between senescence domains of various proteins
including human Spartin (SPG20). Composite tree of various clades created through ML
(Maximum-Likelihood) principle of protein phylogeny. Tree’s spatial arrangement is
rendered by PhyML program and respective statistical integrity of branches determined
by aLRT (approximate Likelihood-Ratio Test). Bootstrap values out of 100 localized on
interior branches of tree. Branch lengths are proportionally consistent with number of
base pair substitutions and, indirectly, comparative points of evolutionary divergence.
Proteins identified by SwissProt number (ex. Q8N0X7) and related genus and species.
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Phospholipids are a class of lipids that form bilayers and are important components of
cellular membranes. The major phospholipids in membranes include phosphatidic acid
(which is a precursor for phosphatidylinositol and thus all phosphoinositides), and
phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylglycerol and cardiolipin (Lemmon, 2008). The most abundant acidic
phospholipids in cell membranes are phosphatidic acid, phosphatidylinositol and
phosphatidylserine. Importantly, many proteins bind to these acidic phospholipids via
specific domains and by these means interact with membranes of different organelles
(Lemmon, 2008).

Phosphoinositides
Phosphoinositides, a subgroup of phospholipids, are a relatively minor component
of cellular membranes, but they play an inordinately large role in interacting with
proteins (Di Paolo and De Camilli, 2006; McLaughlin and Murray, 2005). They were
first recognized for their role in altering membrane composition (Hokin, 1985) and are
involved in signal transduction, membrane trafficking, and cytoskeletal regulation
(Eberhard et al., 1990; Ma et al., 1998; Schu et al., 1993). Phosphoinositides are critical
components of the plasma membrane, the membranes of all intracellular organelles,
including the Golgi complex, endoplasmic reticulum (ER), and endosomes (Jost et al.,
1998; Roy and Levine, 2004; Stenmark et al., 2002; Walch-Solimena and Novick, 1999).
It well known that specific phosphoinositides are associated with membranes of
particular organelles. For example, PI(4,5)P2 (known as PIP2) is found mainly at the
5
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plasma membrane of cells and at membranes of presynaptic terminals in neurons (Jost et
al., 1998), while PI(4)P localizes mainly to the membranes of the Golgi apparatus
(Walch-Solimena and Novick, 1999). Phosphoinositides are phosphorylated inositol
phospholipids, and phosphatidylinositol (PI) is the precursor of all phosphoinositides,
which are formed from phosphorylation of the inositol ring at different positions (Hokin,
1985). Phosphoinositides can be interconverted by specific kinases or phosphatases
acting on the hydroxyl groups of the inositol ring. For example, PI(4)P is phosphorylated
by phosphatidylinositol phosphate 5-kinase to form PI(4,5)P2, and PI(4,5)P2 is in turn
dephosphorylated by SH2 domain-containing inositol-polyphosphate 5-phosphatase to
re-form PI(4)P (Antonsson, 1997).
Many proteins, with a wide array of functions, contain conserved domains that
interact with certain phosphoinositides. These include the highly conserved pleckstrin
homology (PH) and epsin N-terminal homology (ENTH) domains. For example, PH
domains bind to the phosphoinositides PI(4)P, PI(3,4)P2, PI(4,5)P2 and PI(3,4,5)P3
(Kavran et al., 1998). However, the PH domain of a given protein only binds to one
specific phosphoinositide. Thus, the PH domain of four-phosphate-adaptor protein 1
(FAPP1) binds PI(4)P, while the PH domain of phospholipase C δ (PLCδ) binds
PI(4,5)P2 (Garcia et al., 1995; Godi et al., 2004). Similarly, ENTH domains bind to
PI(4)P, PI(3,5)P2 and PI(4,5)P2, but EpsinR’s ENTH domain binds PI(4)P, while Ent3p’s
ENTH domain binds PI(3,5)P2 (Itoh et al., 2001). These specialized interactions between
protein domains and phospholipids result in an arrangement in which a protein may
6
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interact with a specific organelle via binding of its specialized phospholipid-binding
domain to the particular phospholipid present in the membrane of specific organelle.

Phosphoinositide-Interacting Proteins / Domains
Many proteins, via their specialized domains, can rely on binding to
phosphoinositides to confirm their intracellular targets. This is often accomplished
through “coincidence detection.” For example, an adaptor protein has a binding domain
for a specific phosphoinositide, as well as a binding site for a specific cargo protein
(Gaidarov and Keen, 1999). Cargo is transported in a predetermined direction using this
detection process. For example, synaptotagmin protein relies on binding of its C2
domain to PIP2 to verify that vesicles dock at presynaptic membrane terminals (Sutton et
al., 1995). Enzymes, including phospholipase C delta (PLCδ), protein kinase B (PKB)
and phosphoinositide 3-kinase (PI3K), utilize this “phosphoinositide-based code” to
ensure a location where their substrate is present (Bellacosa et al., 1991; Garcia et al.,
1995; Kazlauskas and Cooper, 1990). When activated by stimulation of a G proteincoupled receptor, PLCδ binds to PIP2 via its PH domain in the plasma membrane to
facilitate the breakdown of PIP2 into inositol trisphosphate (IP3) and diacylglycerol
(DAG) (Garcia et al., 1995).
The binding of a protein domain to a given phospholipid is often achieved
through their difference in charge (Lemmon, 2008). Commonly, negatively-charged
(acidic) phospholipids interact with positively-charged (basic) amino acids in the protein
domain (Lemmon, 2008). This mechanism is employed by PH domains, as well as
7
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“Fab1, YOTB, Vac1, EEA1” (FYVE) domains and “Bin, amphiphysin and Rvs” (BAR)
domains (Ferguson et al., 2000; Itoh and De Camilli, 2006; Kutateladze, 2006). While
some of these interactions can be non-specific, they often utilize a secondary cue for
binding, such as changes in calcium levels or membrane curvature (Lemmon, 2008).

Vesicular Transport
Lipids can be transported from one membrane to another via vesicular transport or
non-vesicular transport. Vesicular transport is the canonical pathway for transporting
proteins and lipids throughout the cell. This pathway is defined by the formation of
transport vesicles, which are membrane-enclosed sacs covered with coat protein I or II
(COPI or COPII) or clathrin protein (Robinson and Kreis, 1992). Cargo proteins are
enclosed in these vesicles for transport between the ER, Golgi, plasma membrane and
endosomes, and these proteins are unloaded at their target membranes through membrane
fusion (Schneiter et al., 1999). Lipids, as a part of membranes, are integrally transferred
via transport vesicles (Kaplan and Simoni, 1985; Vance et al., 1991). Proteins rely solely
on vesicular transport to move throughout the cell, while lipids can utilize vesicular and
non-vesicular transport to reach specific intracellular membranes.

Non-vesicular Transport
Non-vesicular lipid transport has been demonstrated to occur between many
organelles, including the ER, plasma membrane, Golgi network, lipid droplets,
mitochondria and peroxisomes (Levine and Klionsky, 2004; Milla et al., 2002). A major
8
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role of this type of lipid transport is to maintain the correct lipid composition of
organellar membranes (Baumann et al., 2005) and to regulate lipid metabolism in cells
(Kumagai et al., 2005). Organelles that are not part of the vesicular trafficking pathway,
including lipid droplets, mitochondria and peroxisomes, do not have the enzymes
necessary to produce their required phospholipids and thus rely heavily on non-vesicular
transport to acquire the necessary phospholipid composition (Levine and Klionsky,
2004; Milla et al., 2002). .
Non-vesicular transport is proposed to occur at membrane contact sites (MCSs),
where membranes are closely apposed (~10-20 nm apart) (Kawano et al., 2006). There
are multiple proposed mechanisms for the transfer of phospholipids at MCSs, but most do
not involve membrane fusion or energy expenditure (Skiba et al., 1996). Because the ER
covers most of the intracellular area (Schnabl et al., 2005), this organelle is heavily
involved in the formation of MCSs with many other organellar membranes, including
mitochondria and the plasma membrane (Pichler et al., 2001; Schnabl et al., 2005). For
example, MCSs facilitate the transfer of phosphatidylserine (PS) from the ER to
mitochondria, where PS is converted to phosphatidylethanolamine (PE) (Liu et al., 2007;
Trotter et al., 1995; Vance et al., 1991). Lipid droplets have been shown to interact with
the ER, endosomes, mitochondria, and peroxisomes (Novikoff et al., 1980; Schmitz et
al., 1985; Szymanski et al., 2007), and recent evidence points to the involvement of
MCSs in at least some of these interactions.
The formation of MCSs between lipid droplets and other organelles seem to be
regulated by Rab proteins (Liu et al., 2007). Rabs are small GTPases that play a role in
9
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membrane traffic, often through regulating membrane-membrane docking (Liu et al.,
2007). At least three Rab species (Rab5, Rab11 and Rab18) have been identified in
association with the membrane of lipid droplets (Liu et al., 2007). A different Rab
species is thought to regulate the interaction between lipid droplets and the membrane of
specific organelle. For example, Rab5 facilitates formation of MCSs between lipid
droplets and early endosomes, while Rab18 helps the formation of MCSs between lipid
droplets and the ER (Liu et al., 2007).

Lipid Transfer Proteins
A specialized class of proteins, called lipid transfer proteins (LTPs), transfers
lipids between the membranes of many intracellular organelles (Bloj and Zilversmit,
1981; Schulz et al., 2009). LTPs have few structural or sequence similarities, but they all
contain a lipid-transfer domain that binds lipid monomers in a “pocket” with a “lid” that
shields the lipid from the aqueous phase during transport (Im et al., 2005). Some LTPs
are single domain proteins, while others are multi-domain proteins that also interact with
specific proteins. For example, many LTPs contain an FFAT (two phenylalanines in an
acidic tract) motif that facilitates their binding to the ER via the integral ER membrane
protein VAP (VAMP-associated protein) (Loewen et al., 2003). The lipid transfer
protein binding to a specific protein present on the membrane allows the LTP to anchor
to specific membrane, which facilitates transport of lipids from the membrane of one
intracellular organelle to another.
10
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There are three major classes of LTPs: sterol transfer proteins, sphingolipid
transfer proteins and phospholipid transfer proteins (Kumagai et al., 2005; Raychaudhuri
et al., 2006; Yamamoto et al., 1991). Examples of phospholipid transfer proteins
include: phosphatidylcholine transfer protein (PCTP), phosphatidylinositol transfer
protein (PITP) and non-specific lipid transfer protein (NSLTP) (Shadan et al., 2008;
Yamamoto et al., 1991). The PI transfer proteins PITPα, PITPβ and RdgB (retinal
degeneration B) are thought to transport PI from the ER to the plasma membrane for
subsequent PI phosphorylation to PI4P and PIP2 ((Cockcroft, 2001)), to maintain the PIP2
pool depleted by PLC (Cosker et al., 2008; Milligan et al., 1997; Xie et al., 2005) and
also to sustain PI4P production at the Golgi complex (Kauffmann-Zeh et al., 1995).
PITPα and PITPβ are single-domain proteins, while RdgB is a multi-domain protein that
includes the FFAT motif to target the protein to the ER (Loewen et al., 2003).

Phospholipids, Endosomal Trafficking and Autophagy
Many neurological diseases involve disruption of normal endocytosis (Bronfman
et al., 2007; Lee et al., 2007; Nixon, 2005; Soreghan et al., 2003). Phosphatidylinositol
3-phosphate (PI3P) is the phospholipid mostly involved in the process of endocytosis and
is found on early endosomes and multivesicular bodies (MVBs) (Wang et al., 2011).
PI3P recruits proteins containing FYVE, PH and PX domains, and it has been shown to
play a role in autophagy, protein sorting and trafficking of endocytic vesicles (Wang et
al., 2011; Wurmser et al., 1999). The kinase responsible for producing PI3P from PI is
phosphoinositide 3-kinase (PIK3C3), which is also called VPS34 (Wurmser et al., 1999).
11
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This kinase is also known to be important in autophagy, protein sorting and vesicular
trafficking, and deletion of the PIK3C3 gene has been shown to cause neuronal
degeneration resulting from disruption of the endosomal pathway (Zhou et al., 2010).
PIK3C3 is widely expressed in the developing and adult brain, and PI3P is expressed in
axons and dendrites of hippocampal neurons, especially in dendritic spines (Wang et al.,
2011). Mice with a deletion in the PIK3C3 gene show loss of dendritic spines,
progressive degeneration of neurons and reactive gliosis (Wang et al., 2011).
This pattern of disease progression is similar to that seen in mouse models of
Huntington’s disease and Alzheimer’s disease (Games et al., 1995; Reddy et al., 1998).
These effects are proposed to be due to defects in endocytic trafficking at synapses
(Wang et al., 2011). Endosomes have recently been shown to play a role in transporting
growth factors from axonal targets back to neurons (Cosker et al., 2008; Wu et al., 2009).
It is possible that the neuronal degeneration observed in PIK3C3 knockout mice is caused
by a lack of trophic support to neuronal cell bodies in the absence of proper levels of
PI3P (Cosker et al., 2008; Wu et al., 2009).

Phospholipids and Cytokinesis
Cell division is crucial to the proper functioning of a cell, and this process is not
complete until the newly formed cells undergo cytokinesis. During cytokinesis, the
cytoplasm of the original cell is constricted through the actions of spindle microtubules in
an intracellular bridge structure called the midbody. The final constriction and cleavage
of the midbody is called abscission (Sagona et al., 2010). Proteins required for
12
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abscission translocate from the centrosome (early in mitosis) to the midbody (during
cytokinesis) (Sagona et al., 2010). The phosphoinositide PI3P has been shown to localize
to the midbody during cytokinesis and recruit proteins required for abscission (Sagona et
al., 2010). These proteins contain the FYVE domain, which binds specifically to PI3P
(Sagona et al., 2010). Depletion of VPS34 kinase (which is responsible for PI3P
formation) results in a greater number of cells arrested in cytokinesis and more
binucleated cells compared to controls (Sagona et al., 2010).
The processes of cell migration and division are essential in development of the
nervous system and share many common features. Signaling from the plasma membrane
controls cytoskeleton polarization, especially where actin polymerization is involved.
PIP2 regulates actin activity and localizes to the cleavage furrow (Janetopoulos and
Devreotes, 2006). The inhibition of PIP2 results in deformation of the cleavage furrow
and inhibition of cytokinesis. PIP2 binds actin and, by this means PIP2 acts as a link
between the plasma membrane and the actin cytoskeleton so that the cleavage furrow can
ingress during cytokinesis (Janetopoulos and Devreotes, 2006). PI(3,4,5)P3 directs actin
polymerization and pseudopodia extension by identifying the leading edge of the cell in
division or migration. The leading edge is enriched in PIP3, while the back of the cell is
depleted of PIP3 (Janetopoulos and Devreotes, 2006). This disparity allows actin
projections to be promoted at the cell’s leading edge and inhibited at the opposite side
(Janetopoulos and Devreotes, 2006). PIP3 levels are controlled by the local activity of
PI3-kinase (PI3K) and phosphatase and tensin homolog (PTEN), which are associated
with the poles and furrow of the cell membrane, respectively (Janetopoulos and
13
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Devreotes, 2006). When depleted of PI3K or PTEN, cells do not undergo cytokinesis
and become multinucleated (Janetopoulos and Devreotes, 2006). Actin projections can
also be found around the entire perimeter of these cells, indicating abnormalities in
cytoskeletal organization (Janetopoulos and Devreotes, 2006).

Spartin and Cytokinesis
Spartin associates with many intracellular organelles, and it also localizes to
important mitotic structures. Spartin is an integral part of the centrosome during
interphase and metaphase, and it is found at the spindle poles during anaphase (Robay et
al., 2006). During cytokinesis, spartin localizes to the midbody, but not spindle
microtubules, and in late cytokinesis, it is found within the intracellular bridge that
connects daughter cells (Robay et al., 2006). In addition, spartin localizes to both the
spindle poles and central spindle (Robay et al., 2006).
While the major, unifying symptoms of the hereditary spastic paraplegias are
lower limb spasticity and weakness, Troyer syndrome patients also present with mild
mental retardation and shortness of stature. Defects in cytokinesis have been reported in
neurological disorders that cause mental retardation (Higgins et al., 2010; Mahmood et
al., 2011). The neurological disorder primary microcephaly presents with an abnormally
small brain, mental retardation, and shortness of stature in some cases (Mahmood et al.,
2011). Autosomal recessive primary microcephaly is caused by mutations in the
abnormal spindle microcephaly related gene (ASPM) (Higgins et al., 2010). ASPM
protein knock-down results in failure to complete cytokinesis (Higgins et al., 2010).
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Mitotic structures also have important roles beyond the cell cycle. The
centrosome is the site of microtubule nucleation in neurons and allows for the generation
of microtubule networks that go on to function in axons and dendrites for subcellular
transport (Robay et al., 2006). Other proteins involved in motor neuron degenerative
diseases have been found to play a role in cytokinesis. For example, alsin, a protein
mutated in the juvenile recessive form of amyotrophic lateral sclerosis (ALS2), also
localizes to the centrosome (Millecamps et al., 2005; Yang et al., 2001). Alsin contains a
PH domain, which allows it to interact with phosphoinositides (Yang et al., 2001).
Truncated alsin lacking a PH domain does not localize to the centrosome (Millecamps et
al., 2005).

Phospholipids and Synaptic Transmission
Endocytosis and exocytosis are essential for neuronal synaptic transmission.
Early studies of the role of phospholipids in these processes showed increased turnover
(via phosphorylation) of phosphoinositides during endocytosis (Hokin and Hokin, 1953).
Synaptic vesicle cycling is a complex process and involves many proteins that bind
phosphoinositides, including the clathrin adaptor proteins AP-2 and AP180, the Ca2+sensing protein synaptotagmin, and the GTPase dynamin (Gaidarov and Keen, 1999; Hao
et al., 1997; Mikoshiba et al., 1999).
Proteins that metabolize phosphoinositides are also involved in synaptic vesicle
cycling. Synaptojanin 1 protein is concentrated in nerve terminals and interacts with
amphiphysin and endophilin proteins that play a role in endocytosis. Synaptojanin is a
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polyphosphoinositide phosphatase, which can act on both PI(4,5)P2 and PI(3,4,5)P3
(Cremona et al., 1999). Synaptojanin 1 knockout mice develop progressive weakness
and ataxia, and die within 15 days of birth (Cremona et al., 1999). Primary neuronal
cultures from these knockout mice show increased PIP2 levels due to decreased
phosphoinositide phosphatase activity, and they also demonstrate an increased number of
clathrin-coated vesicles at nerve terminals (Cremona et al., 1999). Increased levels of
PIP2 appear to be responsible for the accumulation of vesicles (Cremona et al., 1999).
Recordings from hippocampal synapses demonstrated that, when stimuli induce a long
train of action potentials, mutant neurons exhibit a strong depression following
stimulation and take longer to recover than wild-type neurons (Cremona et al., 1999).
This effect is likely due to an inability of mutant neurons to replenish the ready releasable
pool of synaptic vesicles though vesicular recycling (Cremona et al., 1999).
Clathrin coat formation requires proteins, as well as phosphoinositides that allow
those proteins to associate with the vesicle membrane (Cremona et al., 1999). The
proteins amphiphysin and endophilin are clathrin accessory proteins that also bind lipids
(Cremona et al., 1999). When phosphoinositides are present, amphiphysin has a greater
affinity for membranes, which could aid in the formation of clathrin-coated vesicles
(Cremona et al., 1999). However, the cycle is not complete until uncoating occurs, and
that process requires a decrease in the affinity of these proteins for the membrane
(Cremona et al., 1999). When local PIP2 levels are too high, it is possible that uncoating,
and thus, synaptic vesicle recycling, cannot occur.
16

17

As discussed earlier, PIP2 also regulates actin and promotes actin polymerization
(Qualmann et al., 2000). An abnormal increase in PIP2 levels may result in an
overabundance of actin, which could trap vesicles in the reserve pool at nerve terminals
(Cremona et al., 1999). PIP2 regulation of actin also helps to control the association
between the plasma membrane and cytoskeleton (Qualmann et al., 2000). In this
capacity, it may be required for cytoskeleton and plasma membrane remodeling during
endocytosis (Osborne et al., 2001).
Studies have shown that dense core vesicle exocytosis (which is important in the
neuroendocrine system) relies on the lipid transport activity of PITPα and the enzymatic
activity of PIP 5-kinase for the ATP-dependent priming step (Hay and Martin, 1993a;
Hay and Martin, 1993b; Hay et al., 1995). It is thought that PITPα is responsible for
supplying PI to local areas of exocytosis, or for supplying PI directly as a substrate for
kinases (Cunningham et al., 1995; Kearns et al., 1998). PIP 5-kinase is most active at the
plasma membrane, where it could function to convert the PI4P already present in the
membrane of dense core vesicles into PIP2 as the vesicles dock at the plasma membrane
(Cremona et al., 1999). This kinase has been found to be concentrated near sites of
clathrin-coated endocytic intermediate structures, which may allow it to delineate
membrane regions for endocytosis (Osborne et al., 2001). Phosphoinositides are
proposed to “cycle” in tandem with synaptic vesicles during exocytosis and endocytosis
(Cremona et al., 1999). In this proposed model, the primary vesicular membrane
phosphoinositide changes from PI to PI4P to PIP2 as the vesicle forms and exocytosis
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occurs, and then back from PIP2 to PI4P to PI as endocytosis occurs and the vesicle is
uncoated (Cremona et al., 1999).

Spartin and Synaptic Transmission
Preliminary data from our laboratory have suggested a possible role for spartin in
regulating synaptic transmission. In primary cortical mouse neuronal cultures,
endogenous spartin is diffusely expressed throughout the cell body and into the dendrites
and axons of neurons. Following depolarization, endogenous spartin has a more
punctated appearance and colocalizes with the pre-synaptic vesicle protein
synaptophysin. These findings indicate the presence of spartin at synapses of actively
firing neurons. Under these conditions, spartin may be responsible for shuttling
phosphoinositides to the plasma membrane in order to maintain the correct membrane
phospholipid composition and facilitate exocytosis and endocytosis.

Spartin and Lipid Droplets
Spartin also associates with lipid droplets (Eastman et al., 2009; Hooper et al.,
2010). Lipid droplets are classically known as storage vessels for neutral lipids and are
composed of a neutral lipid core surrounded by a phospholipid monolayer (Tauchi-Sato
et al., 2002). The breakdown of these neutral lipids, like triacylglycerol, serves as an
energy source for cells (Zweytick et al., 2000). Recent studies have revealed that lipid
droplets are more complex organelles than previously thought. They have been shown to
contain more than 150 species of phospholipids (Bartz et al., 2007). This finding
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suggests a possible role for lipid droplets in supplying necessary phospholipids to
membrane-bound organelles and regulating the composition of these membranes (Bartz
et al., 2007). Lipid droplets have been shown to interact with many organelles, including
the ER, endosomes, mitochondria, and peroxisomes (Novikoff et al., 1980; Schmitz et
al., 1985; Szymanski et al., 2007; Szymanski et al., 2007). Recent studies provided
evidence that spartin does not bind lipid droplets via their phospholipid monolayer, but
rather via the lipid droplet protein tail-interacting protein 47 kDa (TIP47) (Eastman et al.,
2009). Due to spartin’s capacity to interact with both lipid droplets (via protein-protein
interaction) and phospholipids, spartin may transport phospholipids between membranes
using lipid droplets as vehicles for this transfer.

Lipid Transfer Proteins and Neurological Dysfunction
Many neurological diseases involve disruption of normal membrane lipid
composition. Recently, dysfunction in lipid transfer proteins has been found to play a
role in some of these diseases. Phosphatidylinositol transfer protein α (PITPα) transfers
phosphatidylinositol (PI) to the plasma membrane and is required for PIP2 hydrolysis
(Xie et al., 2005). Neurons derived from PITPα mutants show deficiencies in neurite
outgrowth when stimulated by netrin-1, which promotes axon outgrowth (Xie et al.,
2005). PITPα knock-out mice display reactive gliosis in the cerebellum and brain stem
and demyelination in the spinal cord (Alb et al., 2003). In these mice, cerebellar neurons
have ER deficits, in the form of vacuolations of the smooth ER (Alb et al., 2003), and
motor neuron cell bodies in the ventral horn also die, through a process known as
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aponecrosis, which has features of both apoptotic and necrotic cell death (Alb et al.,
2003). These symptoms may be due to hypoglycemia that also results from PITPα
knock-out, but they are thought to mainly be the result of PITPα being unable to sustain
PI levels in tissue, which leads to dysfunctional conversion of PI into phosphoinositides
such as PI4P and PIP2 (Alb et al., 2003).
In fly eyes, PI is transferred by retinal degeneration B protein (RdgB), which
functions in the fly photoreceptor cell (Milligan et al., 1997). In flies, mutant forms of
this protein lead to retinal degeneration (Milligan et al., 1997). Activation of one
rhodopsin molecule can deplete the entire available PIP2 pool and most of the PI present
in the microvilli (Hardie et al., 2001). Following stimulation, RdgB mutant
photoreceptors recover only 50% of the PIP2 levels of wild-type photoreceptors,
indicating that the pool of PIP2 is not able to be replenished without the functional PI
transfer protein (Hardie et al., 2001).

Summary and Conclusions
Our preliminary data support the hypothesis that spartin is a novel lipid transfer
protein involved in the transfer of negatively-charged phospholipids. We propose that
spartin, via interactions with lipid droplets and membrane phospholipids of other
organelles, may transfer phospholipids from one organellar membrane to lipid droplets
for storage and/or transport to another membrane. We hypothesize that this process
involves spartin’s interaction with the membrane via binding of its plant-related
senescence domain to a major phospholipid in one organelle (the plasma membrane, for
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example), extracting a phospholipid monomer from the membrane bilayer, and then
interacting with a lipid droplet via TIP47 protein and transferring that phospholipid to the
lipid droplet for its storage and/or transport (Fig. 2). From that point, the interaction
between spartin’s MIT domain and Ist1 protein found on midbodies would allow spartin
to transfer the phospholipid from the lipid droplet to the midbody at a separate location
(Fig. 2).
The lipid transfer ability of spartin may have wide-reaching implications for the
disease process of Troyer syndrome. Spartin’s senescence domain allows it to interact
with many different phospholipids, each of which may play a distinct and essential role in
cellular function. The absence of spartin could lead to dysfunctions in processes such as
cytokinesis and synaptic transmission, which could explain the pathophysiology of
Troyer syndrome.
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Model of Spartin as a Novel Lipid Transfer Protein

MIT
N

SD
C

midbody

TIP47

lipid droplet/
endosome
microtubules

Figure 2. A proposed model of spartin acting as a lipid transfer protein. In this
model, spartin binds a phospholipid and transfers it to lipid droplets or endosomes for
storage and subsequently transfers the phospholipid to another organelle. Spartin, via its
senescence domain, binds PI3P in the plasma membrane, while the C-terminus of spartin
interacts with TIP47, which is a resident protein of lipid droplets and endosomes. After
the initial transfer of PI3P to the lipid droplet, spartin interacts, via its MIT domain, with
the midbody protein Ist1 at a second membrane contact site and transfers PI3P from the
lipid droplet to the midbody.
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CHAPTER 2
EXPERIMENTAL METHODS AND RATIONALE

Experimental Design
In vitro studies
In order to further study the binding of the plant-related senescence domain of
spartin to phospholipids, we generated a fusion protein consisting of maltose binding
protein (MBP) fused to the plant-related senescence domain of spartin (amino acids 421607). We did not use the full-length spartin fused to MBP, because we empirically
determined that this fusion protein is not expressed in bacteria. We first generated this
wild-type plant-related senescence domain fusion protein and tested its binding to
phospholipids via lipid-protein overlay assay.
The senescence domain found in spartin is also present in many other proteins,
including the early-responsive to dehydration 7 (ERD7) protein from Arabidopsis
thaliana (NCBI NP_179374.1). To examine the biochemical properties of the
senescence domain in a protein other than spartin, we generated an MBP fusion protein
with the senescence domain of ERD7 protein.
Once we established the binding pattern of the wild-type plant-related senescence
domain to phospholipids, we generated and tested a variety of spartin plant-related
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senescence domain mutants. We generated the mutants “Spr EAT-AAA” (in which the
plant-related senescence domain amino acid sequence Glu-Ala-Thr has been mutated to
Ala-Ala-Ala) and “Spr Sen9K→A” (in which nine positively-charged lysine residues in
the plant-related senescence domain are mutated to alanine residues). We purposely
chose these mutations because the specific amino acids are conserved among the plantrelated senescence domains from proteins in different species, indicating their biological
importance. The changes in phospholipid binding with each of these mutants allowed us
to determine whether a specific amino acid sequence or the overall charge of the
senescence domain plays a important role in the interactions of this domain with
phospholipids.
Based on the results of lipid-protein overlay assays using fusion proteins of these
plant-related senescence domain mutants, we generated two more spartin senescence
domain mutants with fewer mutations, “Spr Sen3K→A” (with 3 lysines mutated to
alanines) and “Spr Sen5K→A” (with 5 lysines mutated to alanines). The changes in
phospholipid binding detected with each of these mutants allowed us to further explore
the nature of the interaction between the senescence domain and phospholipids.

Immunofluorescence
In order to examine the interaction between spartin and specific phospholipids, we
utilized stably-transfected U2OS cells with a GFP-tagged FYVE domain (Cellomics,
Thermo Scientific, Pittsburgh, PA), which binds specifically to PI3P. Using these cells,
we investigated the localization of PI3P at midbodies in the presence of over-expressed
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spartin, endogenous spartin, or upon depletion of spartin. These experiments allowed us
to determine whether spartin levels have any effect on localization of PI3P at midbodies.
The immunofluorescence studies were informative in investigating spartin’s
potential role as a phospholipid shuttle. Spartin’s ability to bind both proteins and
phospholipids may facilitate the transfer of phospholipids between membranes via lipid
droplets. For example, spartin could bind PI3P and facilitate the inclusion of PI3P into
lipid droplets or endosomes, from which PI3P could be transferred to the midbody during
cytokinesis. Given the proper stimulation, it may be possible to track this lipid transfer
through immunofluorescence.

Materials & Methods
Mammalian and bacterial expression constructs
We have generated spartin constructs expressing full-length spartin (amino acids
1-666), the senescence domain of spartin (amino acids 421-607), the senescence domain
of ERD7 (amino acids 69-440) or a mutated senescence domain of spartin. The fulllength human spartin cDNA in the pGW1-hemagglutinin (HA) mammalian expression
vector has been described previously (Bakowska et al., 2007). To generate the spartin
plant-related senescence domain construct, the deletion fragment (amino acids 421-607)
of human spartin was amplified by polymerase chain reaction (PCR) using PfuTurbo
polymerase (Agilent Technologies, Santa Clara, CA). The ERD7 construct was
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purchased from the Arabidopsis Biological Resource Center (Columbus, OH). To
generate the plant-related senescence domain mutant Spr EAT-AAA, three amino acids
(Glu585, Ala586, Thr587) in the plant-related senescence domain were mutated to alanines
(Ala585, Ala586, Ala587). To generate the mutant Spr Sen3K→A, three Lys residues in the
plant-related senescence domain (Lys465, Lys475, Lys481) were mutated to Ala. Two
additional Lys residues from the Spr Sen3K→A mutant (Lys489, Lys578) were mutated to
Ala to generate the Spr Sen5K→A mutant. To generate the mutant Spr Sen9K→A, four
addition Lys residues in the senescence domain (Lys451, Lys 515, Lys 519, Lys 561) were
mutated to Ala. After designing each mutant, the DNA sequences were sent to GenScript
(Piscataway, NJ). All senescence domain fragments were cloned in-frame into the EcoRI
and BamHI sites (on the 5’ and 3’ ends, respectively) of the bacterial expression vector
pMAL-c5E (New England Biolabs, Ipswich, MA), which enables production of MBP
fusion proteins in bacteria.

MBP fusion proteins
All senescence domain of spartin constructs (pMal-Spr 421-607, pMal-Spr EATAAA, pMal-Spr Sen9K→A, pMal-Spr Sen5K→A and pMal-Spr Sen3K→A) and the
senescence domain of ERD7 (pMal-ERD7 69-440) were transformed into Escherichia
coli K12 UT5600 competent cells (New England Biolabs, Ipswich, MA), and expression
of each MBP fusion protein was induced using 0.3 mM isopropyl 1-thio-β-D26

galactopyranoside (IPTG) at 17⁰C overnight. Cells were collected by centrifugation,
lysed, sonicated and incubated with amylose beads in order to bind the fusion protein.
Following incubation, beads were washed with column buffer (200 mM Tris pH 7.4, 200
mM NaCl, 1 mM EDTA, 1 mM DTT, 0.3% NP40, 20 µM leupeptin (Sigma-Aldrich, St.
Louis, MO), 2 µM aprotinin (Sigma-Aldrich), 1.4 µM pepstatin (Research Products Inc.,
Mount Prospect, IL), 1:100 protease inhibitor cocktail (Roche, Branford, CT), 1 mM
PMSF (Sigma-Aldrich)) to remove unbound protein, and then bound protein was eluted
using maltose elution buffer (column buffer with 10 mM maltose (Sigma-Aldrich)).
Fusion protein obtained in elutions was run on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and Coomassie-stained to determine the size and
amount of fusion protein.

Lipid overlay assay
Nitrocellulose membranes pre-spotted with phospholipids (Echelon Biosciences,
Salt Lake City, UT) were processed as previously described (Joshi & Bakowska, 2011).
Strips were incubated overnight at 4⁰C with fusion protein, then washed and treated with
anti-MBP antibody (New England Biolabs), followed by HRP-conjugated secondary
antibody. The ECL Luminata Forte system (Millipore, Billerica, MA) was used to
visualize the signal. Nitrocellulose strips with varying concentrations of MBP-spartin
were processed in parallel to measure the intensity of bound protein using Adobe
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Photoshop 7.0 software (Adobe, San Jose, CA) and then quantify the binding affinity
based on the formula AU = AU0 × ((MBP-Spr)/((MBP-Spr) + Kd), where AU (AU0) is
the (maximal) intensity reading, and (MBP-Spr) is the MBP-spartin 421-607
concentration. Affinity binding curves were generated using Prism Software (GraphPad,
La Jolla, CA).

Cell Culture and Immunofluorescence
U2OS cells were maintained in Dulbecco’s modified Eagle’s medium with
glutamax and supplemented with non-essential amino acids, 10% fetal bovine serum
(FBS) and 0.5 mg/ml G-418 (Research Products, Inc). For immunofluorescence, cells
were plated on glass coverslips and transfected with HA-spartin or HA-empty vector
constructs using Turbofect (Fermentas, Glen Burnie, MA). Cells were also treated with
control or spartin siRNA using Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA).
Spartin knock-down was confirmed by Western blot. Following transfection, cells were
placed in low serum media (0.5% FBS) for 48 hours for cytokinesis studies. Cells were
then returned to regular media for 22-23 hours to synchronize mitosis. The cells were
then fixed with 4% PFA, permeabilized with saponin, and stained with antibodies against
HA (Abcam, Cambridge, MA), endogenous spartin (Protein Tech, Chicago, IL), Aurora
B (Abcam) and/or CEP55 (Abnova, Taipei City, Taiwan).
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In all immunofluorescence experiments, coverslips were mounted with ProLong
Gold Antifade reagent (Invitrogen) and imaged using a Zeiss LSM-510 confocal
microscope (Carl Zeiss MicroImaging, Thomwood, NY) with a 63 x 1.4 NA Plan
Aprochromat oil immersion objective at 1024 x 1024 resolution. Percent of midbodies
with or without PI3P was examined by counting 30-40 midbodies for each condition
(control siRNA and spartin siRNA) per experiment (n = 3).
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CHAPTER 3
RESULTS

In Vitro Studies
Spartin Wild-type Plant-related Senescence Domain
To investigate the binding of spartin’s senescence domain (amino acids 421-607)
to phospholipids, we expressed the senescence domain of spartin as a fusion protein with
maltose binding protein (MBP) in bacteria (Fig. 3A). First, we examined the expression
levels of the senescence domain of spartin in vitro (Fig. 3B) and then used this fusion
protein in a lipid-overlay assay. As a negative control, we used MBP alone. Our results
demonstrated that the plant-related senescence domain of spartin binds to 11 different
negatively-charged phospholipids: phosphatidylinositol (PI), PI(3)P, PI(4)P, PI(5)P,
PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3, phosphatidic acid (PA), phosphatidylserine
(PS) and cardiolipin (Fig. 3C&D, panels on the left). In contrast, MBP alone did not bind
to any phospholipids (Fig. 3C&D, panels on the right). Based on these results, we would
conclude that the senescence domain of spartin specifically binds negatively-charged
phospholipids.

Binding Affinity of Wild-type Senescence Domain
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Figure 3. The senescence domain of spartin binds to many phospholipids. (A)
Schematic diagram of full-length spartin protein (upper panel), including the MIT domain
(18-98) and the plant-related senescence domain (421-607). The senescence domain
(421-607) of spartin was expressed as a fusion protein with MBP (lower panel). (B)
Commassie blue staining shows the expression of MBP alone and MBP-Spr 421-607.
Asterisks depict the degradation products. (C&D) The MBP-Spr 421-607 fusion protein
binds to many phospholipids (panels on the right) pre-spotted on the nitrocellulose
membranes, but MBP alone does not bind to any phospholipids (panels on the left).
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To estimate the affinity of spartin’s plant-related senescence domain for different
phospholipids, we processed five nitrocellulose lipid strips in parallel, and each strip was
incubated with a different concentration of the MBP-spartin senescence domain fusion
protein. Specifically, we used 0, 0.02, 0.1, 0.5 and 2.0 µg/ml of MBP-spartin plantrelated senescence domain (Fig. 4). We quantified the signal intensity of spartin’s binding
at each concentration to each phospholipid and calculated spartin’s affinity constant (Kd)
for each phospholipid tested (Table 1, Fig. 5). We found that the senescence domain of
spartin had the highest affinity for phosphoinositides, with the highest affinity for
PI(4,5)P2 (3.0x10-10 M) and the lowest affinity for phosphatidylserine (PS) (2.1x10-8 M).
This difference in binding affinity parallels the difference in the net charge of these
phospholipids (Fig. 6). PIP2 has a net charge of -3, while PS has a net charge of -1
(Table 2). The plant-related senescence domain of spartin binds very weakly to
phosphatidylglycerol (PG), which has a net charge of -1, and does not bind
phosphatidylethanolamine (PE) and phosphatidylcholine (PC), which both have a net
charge of 0 (Fig. 3). Our findings determined that the plant-related senescence domain of
spartin binds to negatively-charged phospholipids.

ERD7 Senescence Domain
The senescence domain is highly conserved and is present in 150 other proteins
found in different species, including the Arabidopsis thaliana protein early-responsive to
dehydration 7 (ERD7). We used this protein to investigate whether the plant-related
senescence domain in another species also binds to negatively-charged phospholipids.
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We expressed the senescence domain of ERD7 as an MBP fusion protein and used it in a
lipid-overlay assay (Fig. 7A&B). The patterns of phospholipid binding between the
senescence domains of spartin and ERD7 were almost identical (Fig 7C&D). The plantrelated senescence domain of ERD7 has very similar phospholipid binding properties
compared to spartin’s plant-related senescence domain. Determining that the senescence
domain of ERD7 binds to the same phospholipids as the senescence domain of spartin
reinforces the universality of this domain and the importance of determining its function.
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MBP-Spr 421-607

0 µg/ml

0.02 µg/ml

0.1 µg/ml

0.5 µg/ml

2.0 µg/ml

Figure 4. The senescence domain of spartin binds to phospholipids with varying
affinities. Nitrocellulose membranes pre-spotted with phospholipids were incubated with
five different concentrations of MBP-Spr 421-607 fusion protein, as indicated below each
membrane. The left panel indicates the identity of each phospholipid on the control strip
incubated with 0 µg/ml of the senescence domain fusion protein. From left to right,
concentration of the fusion protein increases from 0.02 µg/ml to 2.0 µg/ml (saturation).
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Rank

Phospholipid

Avg. Affinity Constant

1

PI(4,5)P2

3.01 x 10-10 M

2

PI(5)P

3.47 x 10-10 M

3

PI(3,4)P2

3.53 x 10-10 M

4

PI(3,5)P2

4.09 x 10-10 M

5

PI(4)P

4.45 x 10-10 M

6

PI(3,4,5)P3

5.25 x 10-10 M

7

PI

6.55 x 10-10 M

8

PI(3)P

1.01 x 10-9 M

9

PA

4.59 x 10-9 M

10

PS

2.11 x 10-8 M

Table 1. The senescence domain of spartin binds a variety of phospholipids with
high affinity. Affinity constants were calculated using fusion protein concentration (M)
and arbitrary units (AU) of signal intensity from lipid strips. Phospholipids are listed in
descending order of affinity.
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Figure 5. The senescence domain of spartin binds many phospholipids with high
affinity. Saturation binding affinity curves and scatchard plots were generated in Prism
using concentrations (nm) of fusion protein and arbitrary units (AU) of signal intensity
from lipid strips.
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Figure 6. The affinity of spartin’s senescence domain for a given phospholipid is
related to the net charge of the phospholipid. Spartin has the highest affinity (smallest
affinity constant) for phospholipids with the greatest net charge.
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MBP-ERD7

MBP

MBP-ERD7

Figure 7. The senescence domain of Arabidopsis thaliana protein early responsive to
dehydration 7 (ERD7) associates with phospholipids. (A) Schematic diagram of fulllength ERD7 protein (upper panel), including the plant-related senescence domain (69440). The senescence domain (69-440) of ERD7 was expressed as a fusion protein with
MBP (lower panel). (B) Commassie blue staining shows the expression of MBP alone
and MBP-ERD7 69-440. Asterisks depict the degradation products. (C&D) The MBPERD7 69-440 fusion protein binds to many phospholipids (panels on the right) prespotted on the nitrocellulose membranes, but MBP alone does not bind to any
phospholipids (panels on the left).
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Spartin EAT-AAA Senescence Domain Mutant
To further explore the similarities between the senescence domains of spartin and
ERD7, we mutated the conserved amino acid sequence EAT (Glu585, Ala586, Thr587) in the
plant-related senescence domain of spartin to AAA (Ala585, Ala586, Ala587). We
expressed this fusion protein, determined its levels of expression, and used in a lipid
overlay assay. The resulting phospholipid binding pattern was identical to that of the
wild-type spartin plant-related senescence domain (data not shown). Our results
indicated that this conserved amino acid sequence is not involved in binding of the plantrelated senescence domain to phospholipids.

Spartin 3K→A Senescence Domain Mutant
Many amino acids in the plant-related senescence domain are conserved between
spartin and other proteins containing this domain. To explore the importance of the
positively-charged lysines in the senescence domain, we mutated three conserved lysines
(Lys465, Lys475, Lys481) in spartin’s plant-related senescence domain to alanines and
expressed this construct as an MBP fusion protein (Fig 8A&B). After confirming
expression levels of this fusion protein, we used it in a lipid overlay assay. The overall
pattern of phospholipid binding was very similar to that of the wild-type plant-related
senescence domain, with the notable lack of binding to PI and PS (Fig 8C&D). These
two phospholipids are only weakly negatively-charged (-1), which supports the
importance of positively-charged lysine residues in binding to negatively-charged
phospholipids.
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Spartin 5K→A Senescence Domain Mutant
Given that three lysine mutations still did not affect the senescence domain from
binding to the vast majority of phospholipids, we decided to mutate two additional
lysines (Lys489, Lys578) to alanines. These lysine residues are conserved in the plantrelated senescence domain of spartin and ERD7. In the lipid-protein overlay assay, this
“5KA mutant” fusion protein did not bind to PS, PI, PA and cardiolipin. However, this
mutant had a capacity to bind to all other negatively-charged phospholipids (Fig. 9). This
incremental decrease in the overall positive charge of the senescence domain was not
enough to impair spartin’s ability to bind negatively-charged phospholipids.

Spartin 9K→A Senescence Domain Mutant
Mutation of five lysines to alanines within the plant-related senescence domain
affected binding to some phospholipids. Thus, we mutated four more conserved lysines
(Lys451, Lys 515, Lys 519, Lys 561) in spartin’s senescence domain to alanines (for a total of
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A

B

Senescence domain mutated lysines
421EKVAHNILSGASWVSWGLVKGAEITGK

AIQKGASKLRERIQPEEKPVEVSPAVTKGLYI
AKQATGGAAKVSQFLVDGVCT500

C

MBP

MBP-Spr Sen 3K→A

D

MBP

MBP-Spr Sen 3K→A

Figure 8. The spartin senescence domain mutant “Sen 3K→A” does not bind
phosphatidylinositol (PI) or phosphatidylserine (PS). (A) Amino acid sequence
segment featuring the three lysines that were mutated to alanines. The senescence
domain mutant (Sen 3KA) of spartin was expressed as a fusion protein with MBP (lower
panel). (B) Commassie blue staining shows the expression of MBP alone and MBP-Spr
Sen 3KA. Asterisks depict the degradation products. (C&D) The MBP-Spr Sen 3KA
fusion protein binds to many phospholipids (panels on the right) pre-spotted on the
nitrocellulose membranes, with the exception of PI and PS, but MBP alone does not bind
to any phospholipids (panels on the left).
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A

B

Senescence domain mutated lysines
421EKVAHNILSGASWVSWGLVKGAEITGKAIQKGA

SKLRERIQPEEKPVEVSPAVTKGLYIAKQATGGAAKV
SQFLVDGVCTVANCVGKELAPHVKKHGSKLVPESLK
KDKDGKSPLDGAMVVAASSVQGFSTVWQGLECA
AKCIVNNVSAETVQTVRYKYG580

C

MBP

MBP-Spr Sen 5KA

D

MBP

MBP-Spr Sen 9KA

Figure 9. The spartin senescence domain mutant “Sen 5K→A” does not bind
phosphatidylinositol (PI), phosphatidylserine (PS) or cardiolipin. (A) Amino acid
sequence segment featuring the five lysines that were mutated to alanines. The
senescence domain mutant (Sen 3KA) of spartin was expressed as a fusion protein with
MBP (lower panel). (B) Commassie blue staining shows the expression of MBP alone
and MBP-Spr Sen 5KA. Asterisks depict the degradation products. (C&D) The MBPSpr Sen 5KA fusion protein binds to many phospholipids (panels on the right) prespotted on the nitrocellulose membranes, with the exception of PI, PS and cardiolipin, but
MBP alone does not bind to any phospholipids (panels on the left).
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nine mutations) and expressed this construct as an MBP fusion protein (Fig. 10A&B).
The mutation of the nine positively-charged lysines to neutral alanines almost completely
abolished the binding of the senescence domain to any phospholipids, with the exception
of weak binding to PI(3,4)P2 (Fig. 10C&D). Spartin has a high affinity for this
phospholipid (3.5x10-10 M) and PI(3,4)P2 has a net charge of -3, which allows spartin to
interact with it, even when the overall positive charge of the senescence domain has been
greatly reduced. However, the drastic decrease in phospholipid binding when nine
lysines are mutated supports a crucial role for these positively-charged amino acids in
binding negatively-charged phospholipids.

Functional Studies
Colocalization of Spartin and PI3P
In order to study the function of spartin’s senescence domain in binding to
phospholipids, we decided to utilize the immunofluorescence experiments with a specific
phospholipid, namely PI3P. Using U2OS cells stably-transfected with GFP-FYVE (a
protein domain that acts as a marker for PI3P), we first over-expressed spartin, and found
that spartin is present in puncta that colocalize with PI3P at endosomes (data not shown).
Following mitosis synchronization, many of these puncta colocalize with PI3P at
midbodies, as evidenced by co-localization with midbody marker (CEP55). This pattern
of spartin expression is not present in cells transfected with HA empty vector.
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Senescence domain mutated lysines
421EKVAHNILSGASWVSWGLVKGAEITGKAIQKGA

SKLRERIQPEEKPVEVSPAVTKGLYIAKQATGGAAKV
SQFLVDGVCTVANCVGKELAPHVKKHGSKLVPESLK
KDKDGKSPLDGAMVVAASSVQGFSTVWQGLECA
AKCIVNNVSAETVQTVRYKYG580

C

MBP

MBP-Spr Sen 9KA

D

MBP

MBP-Spr Sen 9KA

Figure 10. The spartin senescence domain mutant “Sen 9K→A” almost completely
abolishes binding to phospholipids. (A) Amino acid sequence segment featuring the
nine lysines that were mutated to alanines. The senescence domain mutant (Sen 9KA) of
spartin was expressed as a fusion protein with MBP (lower panel). (B) Commassie blue
staining shows the expression of MBP alone and MBP-Spr Sen 9KA. Asterisks depict
the degradation products. (C&D) The MBP-Spr Sen 9KA fusion protein does not bind
any phospholipids (panels on the right) pre-spotted on the nitrocellulose membranes,
except PI(3,4)P2, and MBP alone does not bind to any phospholipids (panels on the left).
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Importantly, while most endogenous spartin is cytosolic, spartin also colocalizes with
PI3P and CEP55 marker at midbodies (Fig. 11).
PI3P Localization in the Presence and Absence of Spartin
To further explore the role of spartin in PI3P localization, we treated U2OS GFPFYVE cells with control and spartin siRNA. Following spartin knockdown and mitosis
synchronization, fewer cells demonstrated midbodies with PI3P (Fig. 12). By counting
the number of midbodies with and without PI3P in a given population of cells, we
determined that the percent of midbodies with PI3P was significantly reduced in spartindepleted cells relative to cells with normal spartin levels (Fig. 13).
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Phospholipid
PE
PC
PG
PI
PS
PA
Cardiolipin
PI(x)P
PI(x,x)P2
PIP3

Net
Charge
0
0
-1
-1
-1
-2
-2
-2
-3
-4

Wildtype

3KA
Mutant

5KA
Mutant

X
X
X
X
X
X
X
X

X
X
X
X
X

X
X
X
X

9KA
Mutant

X
X

Table 2. Binding of the senescence domain to phospholipids correlates with the net
charge of each phospholipid. The senescence domain does not bind to phospholipids
with a net charge of 0. When three lysines in the senescence domain are mutated to
alanines, binding to phospholipids with a net charge of -1 is lost. When five lysines are
mutated, binding to cardiolipin is also lost. When nine lysines are mutated, binding to all
phospholipids with a net charge of -2 is also lost.
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Figure 11. Endogenous spartin colocalizes with PI3P at midbodies. U2OS cells stablytransfected with GFP-FYVE (PI3P marker) were serum-starved to synchronize mitosis,
fixed and immunostained with anti-spartin (red) and anti-CEP55 (blue) antibodies. The
merged image is shown in the far right panel.
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Figure 12. PI3P localization to midbodies is decreased in the absence of spartin.
U2OS cells stably-transfected with GFP-FYVE (PI3P marker) were treated with control
(upper panels) and spartin (lower panels) siRNA, and then serum-starved to synchronize
mitosis, fixed and immunostained with anti-CEP55 (red) antibody and the nuclear stain
DAPI. The merged image is shown in the far right panel.
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Figure 13. The percent of midbodies without PI3P is increased in cells lacking spartin.
U2OS cells stably-transfected with GFP-FYVE (PI3P marker) were treated with control
(upper panels) and spartin (lower panels) siRNA, and then serum-starved to synchronize
mitosis, fixed and immunostained with anti-CEP55 antibody and the nuclear stain DAPI.
Midbodies were counted as containing or not containing PI3P. A total of 30-40 cells per
condition (control or spartin siRNA) were counted per experiment (n = 3). Error bars =
SEM, p < 0.0398 (Student’s t-test).

CHAPTER 4
DISCUSSION

In Vitro Studies
Wild-type Senescence Domain
Spartin’s plant-related senescence domain has a net charge of +8.5 and binds to a
variety of negatively-charged phospholipids (Protein Charge Calculator, EnCor
Biotechnology Inc, Gainesville, FL). The relative affinity of spartin’s senescence domain
for phospholipids is paralleled by their net charge. The plant-related senescence domain
of spartin does not bind phospholipids with a neutral net charge, and has lower affinity
for weakly negative phospholipids (-1 net charge) than for those phospholipids that are
strongly negative (-3 to -5 net charge). This correlation between affinity and negative
charge supports an important role for the positively-charged lysine residues of the
senescence domain in binding to phospholipids.
Similar to spartin, the plant-related senescence domain of ERD7 binds strongly
negative phospholipids and does not bind neutral phospholipids. In fact, ERD7 does not
even bind weakly negative phospholipids (PI and PS). The net charge of ERD7’s
senescence domain is -5.5 and might indicate why it only bind strongly negative
phospholipids. Even though the overall charge of the ERD7 senescence domain is
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negative, it has 32 lysines (compared to spartin’s 19 lysine residues), which may be
sufficient for binding strongly negative phospholipids.

Spartin Senescence Domain Mutants
Mutating the amino acid sequence EAT (glu-ala-thr) found in many proteins
containing the senescence domain had no effect on the binding of this domain to
phospholipids. Despite the conserved nature of this sequence, it does not appear to play a
role in phospholipid binding. Given that none of the amino acids mutated in the construct
are positively-charged, the lack of a change in phospholipid binding supports the role of
charge in the binding between the senescence domain and phospholipids.
Mutating nine conserved lysines to alanines almost completely abolished binding
of spartin’s senescence domain to any phospholipid (with the exception of PI(3,4)P2. The
wild-type senescence domain of spartin has a very high affinity for PI(3,4)P2, and the
strong negative charge of PI(3,4)P2 would also account for spartin’s continued ability to
bind to this phosphoinositide even when the net positive charge of the senescence domain
is greatly reduced. Mutating nine lysines changes the net charge of the senescence
domain from +8.5 to -2.5 (protein charge calculator, EnCor Biotechnology Inc.), which
appears to be sufficient to preclude binding to almost all phospholipids. However, the
continued ability of the senescence domain to bind PI(3,4)P2 would indicate that the
remaining lysines can still play a role in phospholipid binding and that the structure of the
domain still remains intact.
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Mutating only three conserved lysines to alanines reverted the net charge of the
senescence domain back to positive (+5.5) and restored most of the domain’s binding to
phospholipids, with the exception of PI and PS. The inability of this mutant to bind PI
and PS can be explained by the net charge of these two phospholipids relative to others of
the same class of lipids. PI and PS are only weakly negative (each with a net charge of 1), while the net charge of the other phospholipids bound by spartin ranges from -2 to -5.
Thus, the reduction in positive charge that results from the mutation of three positivelycharged lysines to neutral alanines is enough to abrogate binding of the senescence
domain to these weakly negative phospholipids. This finding strongly supports a
mechanism that involves positively-charged residues in the senescence domain binding to
negatively-charged phospholipids.
Mutating an intermediate number of lysines (five) to alanines changes the net
charge of the senescence domain from +8.5 to +3.5 and results in a phospholipid binding
pattern almost identical to that seen with three mutated lysines. The only phospholipid
bound by the “3 mutant” but not bound by the “5 mutant” was cardiolipin. Given that
cardiolipin has a net charge of -2, it is not unreasonable to conclude that increasing the
net charge of the senescence domain from +5.5 (3 mutant) to +3.5 (5 mutant) affects
binding of the more negatively-charged phospholipids like cardiolipin, while not
affecting those that are highly negatively charged like PIP2 and PIP3.

Functional Studies
Spartin and PI3P
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Over-expressed and endogenous spartin both colocalize with PI3P at midbodies,
which are essential structures in the process of cytokinesis. PI3P is thought to recruit
proteins required for abscission to midbodies so that cytokinesis can be completed. In the
absence of spartin, the number of midbodies with PI3P is greatly reduced. Previous
studies have shown that, in the absence of spartin, many cells are arrested in cytokinesis
and appear binucleated and multinucleated (Lind et al., 2011). The same defects in
cytokinesis result from knockdown of the kinase responsible for PI3P production (Sagona
et al., 2010). Spartin’s function as a lipid transfer protein could explain these defects in
cytokinesis. Sufficient levels of PI3P are required at midbodies in order to recruit PI3Pbinding proteins that are required for abscission (the final step of cytokinesis). Without
spartin present to shuttle PI3P to sites of cytokinesis, abscission may not occur.
Dysfunctional cytokinesis is a feature of some neurological disorders that present
with mental retardation (Higgins et al., 2010). Defects in cytokinesis can also account
for abnormal bone growth (Aszodi et al., 2003). Mild mental retardation and shortness of
stature are both major features of Troyer syndrome, and we propose that these symptoms
are caused by abnormal cytokinesis due to a lack of spartin.

Conclusions
The plant-related senescence domain found in spartin is highly conserved and
present in a variety of proteins in different species of plants, animals and fungi. Despite
its prevalence, the function of this domain had been unknown. In this study, we provide
evidence for a role of plant-related senescence domain in binding to negatively-charged
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phospholipids. Specifically, we show that the binding of the plant-related senescence
domain to the phospholipid PI3P allows spartin to deliver PI3P to midbodies during
cytokinesis so that mitosis can proceed to completion. When mitosis is disturbed, major
physiological defects such as mental retardation and shortness of stature can result.
The varied phospholipid-binding ability of proteins containing the senescence
domain allows those proteins to regulate concentrations of many phospholipids
throughout the cell. By these means, senescence domain proteins can influence a wide
array of essential cellular processes from signaling to cytokinesis to synaptic
transmission. Our findings that spartin delivers PI3P to midbodies can be generalized to
infer a role for spartin in delivering the many other phospholipids it binds to important
intracellular sites. Thus, the failure of spartin to deliver PIP2 to pre-synaptic membranes
could lead to defects in synaptic transmission and cause the lower limb spasticity and
weakness exhibited by Troyer syndrome patients. The role of spartin in shuttling
phospholipids between intracellular membranes could be multi-functional and have many
implications for understanding and treatment of neurological disorders.

Future Directions
Now that we have explored the difference in phospholipid localization in the
presence and absence of spartin, we will next compare this localization using spartin with
the mutated senescence domain (Spr Sen 9KA mutant). This would strengthen our
findings that the senescence domain is responsible for spartin’s binding to phospholipids
55

56

and that this binding is based on the charge of the senescence domain relative to
negatively-charged phospholipids.
We also have preliminary findings that spartin colocalizes with PIP2, and PIP2
hydrolysis may be reduced in the presence of spartin. It is possible that, in binding to
PIP2, spartin blocks binding of PLC and thus inhibits PIP2 hydrolysis. To this end, we
will employ the use of radiolabeled PIP2 in liposomes incubated with and without spartin
and PLC. This will allow us to quantify the amount of PIP2 hydrolyzed in the presence
and absence of spartin.
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